Research programme: cancer therapeutics - Tarveda Therapeutics

Drug Profile

Research programme: cancer therapeutics - Tarveda Therapeutics

Alternative Names: Pentarins™

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Blend Therapeutics
  • Developer Tarveda Therapeutics
  • Class Antineoplastons
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Somatostatin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroendocrine tumours; Small cell lung cancer; Solid tumours

Most Recent Events

  • 27 Jan 2016 Blend Therapeutics is now called Tarveda Therapeutics
  • 07 Jan 2015 Blend Therapeutics in-licenses a ligand technology from an undisclosed Biotechnology company
  • 07 Jan 2015 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top